The medical literature contains a huge number of studies on the safety and performance of novel stent platforms, with primary outcomes usually assessed at 6 months or 1 year. The 5-year analysis from SORT OUT III demonstrates that, when assessing clinical outcomes in stent trials, 1-year follow-up is not enough.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Maeng, M. et al. Differential clinical outcomes after 1 year versus 5 years in a randomised comparison of zotarolimus-eluting and sirolimus-eluting coronary stents (the SORT OUT III study): a multicentre, open-label, randomised superiority trial. Lancet http://dx.doi.org/10.1016/S0140-6736(14)60405-0.
Kandzari, D. E. et al. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J. Am. Coll. Cardiol. 48, 2440–2447 (2006).
Kandzari, D. E. et al. Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents: 5-year follow-up of the ENDEAVOR III (a randomized controlled trial of the Medtronic Endeavor drug [ABT-578] eluting coronary stent system versus the Cypher Sirolimus-Eluting coronary stent system in de novo native coronary artery lesions). JACC Cardiovasc. Interv. 4, 543–550 (2011).
Camenzind, E. et al. Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial. Lancet 380, 1396–1405 (2012).
Miyazawa, A. et al. Comparison of vascular response to zotarolimus-eluting stent versus sirolimus-eluting stent: intravascular ultrasound results from ENDEAVOR III. Am. Heart J. 155, 108–113 (2008).
Valgimigli, M. et al. Randomized comparison of zotarolimus-eluting Endeavor Sprint versus bare-metal stent implantation in uncertain drug-eluting stent candidates: rationale, design, and characterization of the patient population for the ztarolimus-eluting Endeavor Sprint stent in uncertain DES candidates study. Am. Heart J. 166, 831–838 (2013).
Valgimigli, M. et al. The Zotarolimus-eluting Endeavor sprint stent in Uncertain DES candidates (ZEUS). Presented at the 2014 ACC Scientific Sessions.
Rivero, F. et al. Lower levels of in-stent late loss are not associated with the risk of stent thrombosis in patients receiving drug-eluting stents. EuroIntervention 4, 124–132 (2008).
Stefanini, G. G. et al. Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial. Lancet 378, 1940–1948 (2011).
Jensen, L. O. et al. Randomized comparison of everolimus-eluting and sirolimus-eluting stents in patients treated with percutaneous coronary intervention: the Scandinavian Organization for Randomized Trials with Clinical Outcome IV (SORT OUT IV). Circulation 125, 1246–1255 (2012).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Panoulas, V., Colombo, A. Outcomes in coronary stent trials—1 year is not enough. Nat Rev Cardiol 11, 318–320 (2014). https://doi.org/10.1038/nrcardio.2014.63
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrcardio.2014.63
